drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic, gene-modified anti-CD20 chimeric antigen receptor T-cell (CAR-T) therapy; donor-derived T cells engineered to target and kill CD20-positive B cells via T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells are genetically engineered to express an anti-CD20 chimeric antigen receptor; upon binding CD20 on malignant B cells, the CAR activates T-cell effector functions (cytokine release and perforin/granzyme-mediated cytotoxicity) to selectively eliminate CD20-positive B cells.
drug_name
LUCAR-20SP
nct_id_drug_ref
NCT06313957